Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2008
03/12/2008CN100374153C Use of GLP-1 or analogs in treatment of myocardial infraction
03/12/2008CN100374129C Framberry leaf extract effective part and its composition and uses
03/12/2008CN100374125C Pharmaceutical compsn. contg. extract from barleria prionitis linn and its process of prepn
03/12/2008CN100374123C Method for extracting and purifying calf serum protein-removing extract
03/12/2008CN100374121C Tillering onion extract and its application
03/12/2008CN100374120C Powder of flenabane and its preparation method as well as application in making drugs
03/12/2008CN100374045C Method for preparing micron pearl particle and capsule for assisting sleep, tonifying intestine and supplying calcium
03/12/2008CN100374030C Method for preparing micron pearl soybean milk taken at night for assisting sleep, tonifying intestine and supplying calcium
03/12/2008CN100374029C Method for preparing micron pearl soybean milk powder taken at night for assisting sleep, tonifying intestine and supplying calcium
03/11/2008US7342125 Administering derivatives of Kauranoic acid; cachexia, analgesics, in treating immune disorders, as anti-cancer and anti-tumor agents, otitis media, sinusitis, antidiabetic agent
03/11/2008US7342120 Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
03/11/2008US7342117 (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance
03/11/2008US7342034 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
03/11/2008US7342032 Psychiatric and neurological disorders; cannabinoid (cb1) receptor; such as 4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-N-(1-piperidinyl)thiazole-2-carboxamide
03/11/2008US7342029 Substituted indoles
03/11/2008US7342022 Compounds in the treatment of dementia related diseases, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3
03/11/2008US7342019 5, 6-diaryl-pyrazine-2-amide derivatives as CB1 antagonists
03/11/2008US7341871 Recombinant expression vector comprising promoter sequence, age regulatory sequence; can use in treatment of age-related and liver diseases; operably linking nucleic acid sequence, promoter sequence, and age regulatory sequences to produce a transgene, introducing into cell
03/11/2008CA2444561C Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
03/11/2008CA2335104C Arylalkanoylpyridazines
03/11/2008CA2289756C Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
03/06/2008WO2008028118A1 1h-indole-2-carboxylic acid derivatives useful as ppar modulators
03/06/2008WO2008027557A2 Topiramate compositions and methods of enhancing its bioavailability
03/06/2008WO2008027081A1 Processes for the purification of (3r,4s)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-(4-fluorophenyl)-3-oxopropyl] azetidin-2-one
03/06/2008WO2008026965A1 Substituted pyrrolo[4,3-b]indoles, combinatorial and focused libraries, pharmacological composition and a method for the production and use thereof
03/06/2008WO2008026785A1 Lipid metabolism improving agent containing hydrogen molecule
03/06/2008WO2008026668A1 Medicinal composition containing insulin resistance improving agent
03/06/2008WO2008026564A1 Urea derivative
03/06/2008WO2008026563A1 Hydrazine amide derivative
03/06/2008WO2008025870A1 Compositions useful especially for treatment or prevention of metabolic syndrome
03/06/2008WO2008025822A1 Diazolodiazine derivatives as kinase inhibitors
03/06/2008WO2008025800A1 Pyrimidine compounds for treating gpr119 related disorders
03/06/2008WO2008025799A1 Pyridazine compounds for treating gpr119 related disorders
03/06/2008WO2008025798A1 Pyridine compounds for treating gpr119 related disorders
03/06/2008WO2008025539A1 Heterocyclic fxr binding compounds
03/06/2008WO2008025450A1 Methods of lowering glucose levels
03/06/2008WO2008025249A1 The use of the effective section of alkaloids from ramulus mori for preparation of a hypoglycemig agent
03/06/2008WO2008006547A3 Pyrrolopyrimidines for pharmaceutical compositions
03/06/2008WO2008005964A3 Phosphonate and phosphinate compounds as glucokinase activators
03/06/2008WO2008003484A8 Agent containing chrysin and cholic acid for reducing weight, accelerating lipid catabolism, and/or restricting calories
03/06/2008WO2007135461A3 Pharmaceutical compositions comprising implitapide and methods of using same
03/06/2008WO2007131778A3 Diagnostic and therapeutic uses of peptides for pre-forms of type 2 diabetes and conditions associated therewith
03/06/2008WO2007128761A3 Uses of dpp-iv inhibitors
03/06/2008WO2007126993A3 Multi-membrane immunoisolation system for cellular transplant
03/06/2008WO2007102999A3 Cb1 antagonists and inverse agonists
03/06/2008WO2007036920A3 Therapeutic use of polyanhydroglucronic acid
03/06/2008US20080058431 Screening compounds to treat, stabilize, or prevent a higher than desired total body weight or a higher than desired percentage of body fat if the compound increases Shp2 activity by binding of Shp2 on the leptin receptor; Shp2 agonist; dietetics; eating disorders; glandular disorders
03/06/2008US20080058423 Melanin concentrating hormone antagonists
03/06/2008US20080058388 Administering rosiglitazone and/or salts, and glimepiride to mammals for prophylaxis of non-insulin dependent diabetes; metabolic disorders; hypoglycemic agents
03/06/2008US20080058385 For treatment of Type II diabetes, obesity
03/06/2008US20080058381 Such as 1-[bis(4-chlorophenyl)methyl]-3-[(3,5-difluorophenyl)(methylsulfonyl)methylene]azetidine
03/06/2008US20080058379 Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
03/06/2008US20080058370 For treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease; kits
03/06/2008US20080058365 Fused heterocyclic compounds
03/06/2008US20080058360 Soluble CD40L (CD 154) as a prognostic marker of atherosclerotic diseases
03/06/2008US20080058354 Treating erectile dysfunction and female sexual dysfunction; side effect reduction; 1-ethyl-3-(2-hydroxyethyl)-7-(3-bromo-4-methoxyphenyl)-8-(2-hydroxycyclopenylamino)-1,2,3,6-tetrahydro-7H-purine-2,6-dione for example
03/06/2008US20080058340 MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds
03/06/2008US20080058339 4-phenyl-3-substituted pyridazine compounds such as tert-Butyl 4-[((6-[4-(methylsulfonyl)phenyl]pyridazin-3-yl)oxy)methyl]-piperidine-1-carboxylate; agonists of the G-protein-coupled receptor GPR119; diabetes and obesity; use with a dipeptidyl peptidase IV (DPP IV) inhibitor
03/06/2008US20080058313 Tetrahydro-2h-indazole pyrazole cannabinoid modulators
03/06/2008US20080058310 High-density lipoprotein-cholesterol level elevating agent
03/06/2008US20080058306 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
03/06/2008US20080058305 Processes for the purification of (3R,4S)-4-(4-hydroxy-protected-phenyl)-1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-oxopropyl]azetidin-2-one
03/06/2008US20080058300 use of compound 1436, an aminosterol tyrosine phosphatase (PTP1B) inhibitor also known as trodusquemine; obese patient also has type II diabetes, high serum cholesterol, sleep apnea, pickwickian syndrome and nonalcoholic steatohepatitis
03/06/2008US20080058292 Administering synergistic mixture of adipocyte proteinG antagonist and peroxisome proliferator activator antagonist; concurrent administering niacin and non-steroid antiinflammatory drug
03/06/2008US20080058270 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
03/06/2008US20080058264 Mixture of leucine and threonine
03/06/2008US20080058252 Use of C5A receptor antagonist in the treatment of fibrosis
03/06/2008US20080057515 Beta-like glycoprotein hormone polypeptide and heterodimer
03/06/2008US20080057142 Compositions and methods for weight-loss and weight-loss maintenance in daytime and nighttime formulation
03/06/2008US20080057069 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue
03/06/2008US20080057044 Lactobacillus Plantarum with Body-Fat Reducing Activity and the Foods Containing Them
03/06/2008US20080057004 Albumin-insulin fusion proteins
03/06/2008CA2696874A1 The use of the effective fraction of alkaloids from mulberry twig in preparing hypoglycemic agents
03/06/2008CA2667330A1 Lipid metabolism improving agent containing hydrogen molecules
03/06/2008CA2662274A1 Chemical compounds
03/06/2008CA2661598A1 Methods of lowering glucose levels
03/06/2008CA2661371A1 Pyrimidine compounds for treating gpr119 related disorders
03/06/2008CA2660699A1 Pyridine compounds for treating gpr119 related disorders
03/06/2008CA2647981A1 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring
03/05/2008EP1895005A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
03/05/2008EP1894930A1 Thiazole derivative
03/05/2008EP1894929A1 Process for producing thiazolidinedione compound and production intermediate thereof
03/05/2008EP1894928A1 Heterocyclic fxr binding compounds
03/05/2008EP1894919A1 Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
03/05/2008EP1894911A1 Vitamin d-like compound
03/05/2008EP1894576A1 Novel triglyceride reducing agent
03/05/2008EP1894567A1 Concomitant pharmaceutical agents and use thereof
03/05/2008EP1893603A1 Piperidin-4-yl-amide derivatives and their use as sst receptor subtype 5 antagonists
03/05/2008EP1893592A1 Oxadiazole derivatives as dgat inhibitors
03/05/2008EP1893582A2 Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
03/05/2008EP1893224A1 Use of plant cell membrane for the for the treatment of obesity
03/05/2008EP1893222A2 Anti-hypercholesterolemic compounds
03/05/2008EP1893219A2 Use of spirostenols to treat mitochondrial disorders
03/05/2008EP1893208A1 Pharmaceutical composition comprising a 1-(3-chlorophenyl)-3-alkylpiperazine for treating apetite disorder
03/05/2008EP1697362B1 Crf receptor antagonists and methods relating thereto
03/05/2008EP1411919B1 (-)-olivil as antioxidant
03/05/2008EP1383733B1 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
03/05/2008EP1267642B1 Composition comprising resistant starch and unsaturated fats
03/05/2008EP1045836B1 Pyridones as src family sh2 domain inhibitors
03/05/2008EP0989993B1 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
1 ... 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 ... 1298